| Home | E-Submission | Sitemap | Contact Us |  
J Korean Cancer Assoc > Volume 29(1); 1997 > Article
Journal of the Korean Cancer Association 1997;29(1): 103-110.
A Phase II Study of AP (Doxorubicin, Cisplatin) Chemotherapy in Patients with Advanced Hepatocellular Carcinoma
Jung Ae Lee, Yoon Koo Kang, Chang Min Kim, Jin Oh Lee, Tae Woong Kang
1Department of Internal Medicine, College of Medicine, Hallym University, Korea.
2Korea Cancer Center Hospital, Seoul, Korea.
Hepatocellular carcinoma (HCC) is the most common form of primary hepatic carcinoma and is considered to be a highly malignant tumor with poor prognosis. We evaluated the efficacy and toxicities of AP (doxorubicin, cisplatin) comnination chemotherapy in hepatocellular carcinoma.
Between October 1989 and February 1991, 21 previously untreated patients with advanced hepatocellular carcinoma were entered and treated with AP combination chemotherapy (adriamycin 60 mg/m2, D1 and cisplatin 60 mg/m2, D1, repeated every 3 weeks).
Among 14 evaluable patients, there was no complete response and 5 patients (36%; 95% C.I=10~62%) achieved partial response. The median survival time of all 21 patients was 17 weeks, and 63 weeks in responders (n=5) and 14 weeks in nonresponders (n=16), and the difference in two groups was statistically significant (p<0.05). The median time to progression of 14 evaluable patients was 13 weeks, and 49 weeks in the responders (n=5) and 6 weeks in the nonresponders (n=9), and the difference in two groups was statistically significant (p<0.05). Myelosuppression was minimal and non-hematologic toxicities were gererally mild and well tolerated.
The results suggest that the combination chemotherpy of AP seems to be an effective regimen for hepatocellular carcinoma. Further trials are recommended for its true efficacy.
Key words: Advanced hepatocellular carcinoma;Chemotherapy;Adriamycin;Cisplatin
Editorial Office
Korean Cancer Association
Room 1824, Gwanghwamun Officia
92 Saemunan-ro, Jongno-gu, Seoul 03186, Korea
TEL: +82-2-3276-2410   FAX: +82-2-792-1410   E-mail: journal@cancer.or.kr
About |  Browse Articles |  Current Issue |  For Authors and Reviewers
Copyright © Korean Cancer Association.                 Developed in M2PI